⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8256801 | 0.92 | MAPT (0.45) | — | |
| SCHEMBL21610736 | 0.91 | RAB9A (0.44) | — | |
| SCHEMBL5708677 | 0.91 | RAB9A (0.44) | — | |
| SCHEMBL10194544 | 0.90 | RAB9A (0.44) | — | |
| SCHEMBL2671753 | 0.90 | RAB9A (0.44) | — | |
| SCHEMBL3395754 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL22860589 | 0.86 | HRH4 (0.42) | — | |
| SCHEMBL22448993 | 0.86 | ALDH1A1 (0.41) | — | |
| SCHEMBL2583252 | 0.84 | ADORA1 (0.46) | — | |
| SCHEMBL2583255 | 0.84 | ADORA1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023184327-A1 | KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023001061-A1 | CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| EP-4001276-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021132577-A1 | ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREFOR | 日本たばこ産業株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2013150416-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8093379-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| EP-0355353-B1 | Cycloalkylthiazole derivatives | HOFFMANN LA ROCHE (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5001140-A | Cycloalkylthiazoles | HOFFMANN-LA ROCHE INC. (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0355353-A2 | Cycloalkylthiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-02-28 | — | — | EP | disclosed |